In the first half of 2019, are API manufacturers doing well?

[trends of pharmaceutical network industry] affected by environmental protection, high pressure, market and other factors, the shuffling of API industry is intensified, a large number of enterprises stop production and withdraw from the market, which makes the supply of API Market tense, causing high concern in the industry Now that the first half of 2019 has passed, what are the achievements of API manufacturers? According to the current disclosure of API enterprises, the overall results are mixed Fuxiang shares: in the first half of the year, the net profit decreased by 13.49% year on year On July 30, Fuxiang shares issued the semi annual report of 2019 The announcement shows that during the reporting period, the revenue reached 592 million yuan, down 4.74% year on year; the net profit attributable to shareholders of listed companies was 114 million yuan, down 13.49% year on year According to the public information, Fuxiang mainly focuses on the R & D, production and sales of characteristic antibacterial APIs and intermediates The company said that within the API sector, the contradiction between supply and demand of some varieties is increasing Affected by the "three · two · one water incident", the bulk production of APIs, intermediates and other pharmaceutical and chemical raw materials enterprises in Northern Jiangsu has been suspended, resulting in a tight supply of some kinds of APIs and intermediates Minoua: in the first half of the year, the non net profit increased by more than three times On July 30, minoua issued the 2019 half year report In the first half of 2019, the operating revenue reached 561 million yuan, an increase of 61.31% over the same period of the previous year The net profit attributable to the parent company was 86.2942 million yuan, an increase of 91.57% over the same period of the previous year The net profit after deduction was 78.2086 million yuan, an increase of 312.21% over the same period of the previous year The company said that the reason for the increase in performance, in addition to the merger of Liaoyuan pharmaceutical industry, was mainly due to the rise in volume and price of valsartan, the core API, and the gradual increase in volume of other key varieties with the development of customers Changshan Pharmaceutical Co., Ltd.: the net profit in the first half of the year increased by 0% - 30% in the same period According to the mid-2019 report issued by Changshan Pharmaceutical Co., Ltd in July, during the reporting period, the net profit attributable to the shareholders of the listed company was 106 million yuan - 138 million yuan, an increase of 0% - 30% over the same period last year The company said that the main reason for the performance growth was that the sales volume of the main product low molecular weight heparin water injection continued to maintain a rapid growth trend, while the price of unfractionated heparin API continued to rise According to the public information, Changshan Pharmaceutical Co., Ltd is a leading enterprise with a complete heparin product industry chain, which can simultaneously engage in the research, development, production and sales of heparin APIs and heparin preparations Fu'an Pharmaceutical Co., Ltd.: the net profit in the first half of 2019 released by Fu'an Pharmaceutical Co., Ltd decreased slightly compared with the same period last year According to the performance forecast of the first half of 2019 released by Fu'an Pharmaceutical Co., Ltd., the net profit attributable to shareholders of Listed Companies in the reporting period was 150 million yuan to 170 million yuan, down 1.6% - 13.18% compared with the same period last year During the reporting period, the company's preparations, intermediates and distribution business increased steadily, but the sales revenue of API decreased year on year, which made the company's net profit slightly decreased year on year According to the public information, Fuan pharmaceutical mainly produces and sells sterile APIs, non sterile APIs, research and development of fine chemical products, special chemicals, etc Yifan pharmaceutical: in the first half of the year, the year-on-year growth was 59.1% Dongcheng pharmaceutical disclosed the China Daily on July 31, 2019 In the first half of 2019, the company achieved a total operating revenue of 1.33 billion, a year-on-year growth of 39.6%; and a net profit attributable to the parent of 180 million, a year-on-year growth of 59.1% From the perspective of business structure, "API related products" and "nuclide drugs" are the main sources of Dongcheng pharmaceutical's business income During the reporting period, in terms of API business, in the first half of 2019, due to the price rise of African CSFV heparin products and the multiple factors of increasing market development, API sector exceeded the expected performance target